Maxeon Solar Technologies Ltd. engages in the manufacturer and marketer of premium solar power technology. Its products include Maxeon Line of IBC solar cells and panels, and the Performance Line of shingled solar cells and panels. The firm owns and operates solar cell and panel manufacturing facilities located in France, Malaysia, Mexico and the Philippines, as well as participate in a joint venture in China with TZS. The company was founded in 2019 and is headquartered in Singapore.
Genasys, Inc. engages in the provision of critical communications hardware and software solutions and a multi-channel approach to deliver geo-targeted alerts, notifications, instructions, and information before, during, and after public safety threats and critical business events. Its communications platform includes Genasys Emergency Management (GEM) applications, National Emergency Warning Systems (NEWS), and LRAD long-range voice broadcast systems. The firm operates through the following segments: Hardware and Software. The company was founded by Elwood G. Norris in 1980 and is headquartered in San Diego, CA.
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
AquaBounty Technologies, Inc. engages in the provision of land-based aquaculture services. It includes farming of aquatic organisms such as fish, shellfish, crustaceans, and aquatic plants. The firm focuses on a salmon product, a bioengineered Atlantic salmon that can grow to market size faster than conventional farmed Atlantic salmon. The company was founded by Elliot Z. Entis and Garth L. Fletcher on December 17, 1991 and is headquartered in Harvard, MA.
CS Disco, Inc. engages in the provision of legal technology solutions. It operates through the United States and All Other Countries segments. The company was founded by Kiwi Camara, Kent Radford, Gabe Krambs and Barry Hagan in 2012 and is headquartered in Houston, TX.
22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.